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Personalized Clinical Decision 
Making Through Implementation of 
a Molecular Tumor Board: A German 
Single-Center Experience
INTRODUCTION
Personalized cancer medicine uses molecular 
biomarkers for standard-of-care treatment strat-
ification, such as activating BRAF mutations for 
the treatment of melanoma with BRAF inhib-
itors.1 In parallel, it has become evident that 
therapeutic strategies with targeted drugs are 
no longer specific for the treatment of distinct 
entities but rather for particular molecular pro-
files across different cancers.2-4 Thus, testing 
for single-drug targets can provide therapeutic 
information, but its predictive value may vary 
between entities. Although an activating BRAF 
V600E mutation will predict response to BRAF 
inhibitors in melanoma,1 it may not do so in 
colorectal cancers because of epidermal growth 
factor receptor (EGFR) feedback activation with 
requirement of additional EGFR targeting.5,6 
Moreover, non-V600 BRAF mutations might 
not be responsive to BRAF inhibition at all.7 
Thus, one-mutation–one-drug approaches may 
be ineffective, especially in heavily pretreated 
patients with cancer. Underlying causes include 
Purpose Dramatic advances in our understanding of the molecular pathophysiology of 
cancer, along with a rapidly expanding portfolio of molecular targeted drugs, have led 
to a paradigm shift toward personalized, biomarker-driven cancer treatment. Here, we 
report the 2-year experience of the Comprehensive Cancer Center Freiburg Molecular 
Tumor Board (MTB), one of the first interdisciplinary molecular tumor conferences 
established in Europe. The role of the MTB is to recommend personalized therapy for 
patients with cancer beyond standard-of-care treatment.
Methods This retrospective case series includes 198 patients discussed from March 2015 
through February 2017. The MTB guided individual molecular diagnostics, assessed 
evidence of actionability of molecular alterations, and provided therapy recommendations, 
including approved and off-label treatments as well as available matched clinical trials.
Results The majority of patients had metastatic solid tumors (73.7%), mostly progressive 
(77.3%) after a mean of 2.0 lines of standard treatment. Diagnostic recommendations re-
sulted in 867 molecular diagnostic tests for 172 patients (five per case), including exome 
analysis in 36 cases (18.2%). With a median turnaround time of 28 days, treatment rec-
ommendations were given to 104 patients (52.5%). These included single-agent target-
ed therapies (42.3%), checkpoint inhibitors (37.5%), and combination therapies (18.3%). 
Treatment recommendations were implemented in 33 of 104 patients (31.7%), of whom 
19 (57.6%) showed stable disease or partial response, including 14 patients (7.1% of the 
entire population) receiving off-label treatments.
Conclusion Personalized extended molecular-guided patient care is effective for a small 
but clinically meaningful proportion of patients in challenging clinical situations. Limit-
ed access to targeted drugs, lack of trials, and submission at late disease stage prevents 
broader applicability, whereas genome-wide analyses are not a strict requirement for 
predictive molecular testing.
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the challenge to discriminate relevant muta-
tions and pathway aberrations from background 
and passenger mutations,8 the clonal molecular 
intra- and intertumoral heterogeneity,9,10 and 
dynamic changes in the molecular composition 
of cancer, especially if treatment leads to selec-
tion of resistant subclones. Examples include 
the selection of RAS mutant clones in colorectal 
cancer treated with EGFR antibodies, such as 
cetuximab or panitumumab,11 or the acquisition 
of a secondary EGFR T790M kinase domain 
mutation mediating resistance to EGFR kinase 
inhibitors, such as gefitinib or erlotinib in non–
small-cell lung cancer.12,13
This increasing amount of complexity requires 
tools to translate individual information into 
personalized treatment concepts. A molecular 
tumor board (MTB) represents a platform that 
integrates clinical and molecular parameters for 
clinical decision making. Here, we report the 
2-year experience of the Comprehensive Cancer 
Center Freiburg MTB that provides personal-
ized treatment recommendations on the basis 
of individual molecular diagnostics. We hereby 
present detailed data on patient characteristics, 
treatment recommendations, clinical adherence 
to recommendations, and outcomes of treated 
patients.
METHODS
MTB Implementation and Organization
The MTB is run by an interdisciplinary team 
of medical and scientific experts with a focus 
on clinical and translational oncology and com-
putational and molecular biology. Cases are 
submitted using an online registration and doc-
umentation system (Appendix Fig A1). Each case 
is assigned to a clinician scientist with expertise 
in the specific cancer type (entity expert), who 
reviews the literature and available clinical tri-
als. In parallel, the molecular pathology team 
reviews the individual tumor pathology and 
sets up a presentation of already performed and 
suggested diagnostic tests. The initial discus-
sion includes a clinical case presentation, review 
of the pathology data and the tumor-specific 
genetic landscape, known molecular predictive 
or prognostic markers, active clinical trials, and 
potential in- and off-label molecular targeted 
treatments. The molecular diagnostic requests 
are performed using certified and standard 
operating procedure (SOP)–driven processes. 
Diagnostic results are presented to the MTB by 
the molecular pathology and/or the computa-
tional biologist team. After discussion, treatment 
recommendations are given and are supported 
by levels of evidence (Data Supplement). These 
are based on published molecular biomarker 
recommendations.14
Patients and Patient Informed Consent
All patients discussed (n = 198) were included 
in this retrospective single-center case series. 
All molecular diagnostic tests were conducted 
in accordance with the medical treatment con-
tract signed by each patient. Patient tissue was 
stored in the local biobank and required a signed 
informed consent, approved by the University 
of Freiburg institutional review board. Patients 
with individual or family history indicative 
of germline disease-causing mutations were 
referred to the Institute of Human Genetics 
for counseling and possibly germline genetic 
analyses.
Diagnostic Molecular Pathology
Appropriate tissues were subjected to molecular 
analyses as recommended by the MTB (Fig 1). 
All analyses were carried out according to rou-
tine pathology laboratory testing procedures, 
with assays being nationally validated and cer-
tified. Targeted next-generation sequencing 
(tNGS) included a custom-designed hotspot 
eight-gene panel (designed by S.L. and produced 
by Illumina, San Diego, CA), a BRCA1/2 panel 
(produced by Illumina), a hotspot 48-gene panel 
(TruSeq Amplicon Cancer Panel, Illumina), and 
a 54-gene myeloid panel (TruSight Myeloid 
Sequencing Panel, Illumina).15-17
Investigational Genetic Tumor 
Characterization
Whole-exome sequencing (WES) and RNA 
sequencing (RNA-Seq) were performed on 
tumor tissue. Complementary germline DNA 
was obtained from peripheral blood or healthy 
tissue. Only nonsynonymous mutations detected 
with a variant allele frequency > 10% and listed 
with a minor allele frequency < 0.001% by the 
Exome Aggregation Consortium18 were reported. 
Single nucleotide variations were classified 
according to ClinVar,19 COSMIC,20 dbSNP,21,22 
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hotspot mutation23,24 (http://cancerhotspots.org/ 
#/home), TARGET db (http://archive.broadin-
stitute.org/cancer/cga/target), drug-gene inter-
action (DGIdb; http://www.dgidb.org),25 and 
CADD (http://cadd.gs.washington.edu), and 
categorized according to the predicted impact on 
protein function by Condel.26-31 Copy number 
alteration analysis was performed using Con-
trol-FREEC.32 The STAR33 aligner was used 
to align and infer the gene expression level. 
FusionCatcher (https://doi.org/10.1101/011650) 
was used to predict gene fusions. Differentially 
expressed genes were identified using the limma- 
voom package from R/Bioconductor.34,35
RESULTS
From March 2015 through February 2017, 49 
MTB meetings were attended by a median of 16 
physicians and scientists, ensuring continuous 
interdisciplinary data interpretation and discus-
sions with diagnostic and therapeutic decision 
making. The workflow of the MTB included a 
case and literature review, molecular diagnostic 
recommendations, and follow-up discussions 
of the molecular diagnostic results, including 
treatment recommendations (Appendix Fig A1). 
Thus, a total of 385 case discussions were held 
for 198 patients (1.9 discussions per patient; 





















































































































































































































































































































































































































































































































Fig 1. Molecular diagnostic testing. (A) The panels depict the type of molecular diagnostic testing performed (left panel) and specify the number 
of immunohistochemical stains (one to eight antibodies) per case (middle panel) as well as the type of targeted next-generation sequencing (tNGS) 
library sequenced (right panel). tNGS was performed either by a custom panel (eight-gene panel), a 48-gene panel (TruSeq Amplicon Cancer 
Panel, Illumina, San Diego, CA), a 54-gene myeloid panel (TruSight Myeloid Sequencing Panel, Illumina) or a custom BRCA1/2 consortium panel. 
(B) The bar plot depicts the number of sequence variants detected in tumor DNA of 139 patients using tNGS. The bars indicate the numbers of 
mutations in a given gene (black) and sequence variants that are annotated in COSMIC (gray). The numbers of actionable mutations is shown in 
green (drug sensitizing) and red (drug resistance). (C) The bar plot depicts the 30 most frequently somatic mutated genes of 36 patients analyzed by 
whole-exome sequencing (WES). The colors indicate different tumor entities. Mutations with a variant allele frequency > 10% and a minor allele 
frequency < 0.001 were considered. The GI tumor category includes liver, pancreas, stomach, and esophagus. CUP, carcinoma of unknown primary; 
HPV, human papillomavirus; IHC, immunohistochemistry; ISH, in situ hybridization; MSI, microsatellite instability.
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Table 1). In total, 505 structured recommenda-
tions were given (2.5 per patient; Table 1). These 
included 305 diagnostic and 104 treatment rec-
ommendations.
Patient Characteristics
The average patient age at the time of the initial 
MTB presentation was 58 years (range, 1 to 85 
years). Detailed patient characteristics are listed 
in Table 2. One hundred ninety-one of 198 
patients (96.4%) had an underlying malignant 
condition. Patients with solid tumors largely 
outbalanced hematopoietic malignancies (95.5% 
v 4.5%). Soft tissue tumors (12.6%), CNS 
tumors (11.1%), and carcinoma of unknown 
primary (CUP; 10.1%) were the most frequent 
tumor entities. The majority of patients (n = 146; 
73.7%) suffered from metastatic disease, and 
77.3% (n = 153) showed disease progression 
while receiving the standard treatment (Table 2). 
The mean time interval from diagnosis to first 
MTB discussion was 33.6 months (range, 1 to 
541 months). Patients with treatment-refractory 
metastatic disease had undergone a mean of 2.0 
(range, one to 11) lines of systemic pretreat-
ments. A minority of the patients was referred 
to the board with rare tumors (n = 33; 16.7%) or 
because of young age (n = 3; 1.5%).
Molecular Diagnostic Testing
The distribution of molecular diagnostic recom-
mendations is shown in Table 1. For 172 patients 
(86.9%), 305 recommendations were given and 
included routine molecular tests in 153 (89%), 
extended genetic analysis in 69 (40.1%), and 
both in 53 (30.8%) patients. Rebiopsies were 
recommended in 15 cases, mostly because of 
lack of adequate tissue. Of all diagnostic recom-
mendations, 234 (76.7%) were implemented, 
resulting in 867 single diagnostic tests (mean, 
five per patient), including 815 routine molec-
ular tests and 52 extended genetic analyses (Fig 
1A, left panel).
Routine molecular diagnostics included immu-
nohistochemical (IHC) staining for biomarkers 
(n = 492; Fig 1A, middle panel), such as pro-
grammed death-ligand 1 (PD-L1) and mismatch 
repair proteins, in situ hybridizations (ISH) for 
gene copy number analyses (n = 92), and test-
ing for microsatellite instability and/or gene 
hotspot variations (n = 89) and tNGS (n = 139; 
Fig 1A). The latter included libraries of differ-
ent gene panels (Fig 1A; right panel). The most 
frequent COSMIC annotated sequence variants 
detected by tNGS occurred in TP53, BRCA1, 
KDR, KIT, KRAS, PIK3CA, BRCA2, and BRAF 
(Fig 1B; Data Supplement). Therapeutically rel-
evant mutations in hotspot regions were iden-
tified in 41 of 139 patients (29.5%), including 
drug-sensitizing variants in BRAF, PIK3CA, 
IDH1, EGFR, and KIT, as well as drug resistance 
variants in KRAS and NRAS.
Extended genetic analyses including exome and 
transcriptome assays were performed for 36 
patients (18.2%; WES and RNA-Seq: n = 35; 
RNA-Seq only: n = 1). In those, we identified 
a total of 5,335 variants, including 18 COSMIC 
annotated hotspot mutations (Data Supple-
ment). Sixteen were classified as therapy rele-
vant according to the DGI and the TARGET 
databases. Among the remaining non-hotspot 
mutations, 1,518 were annotated in COSMIC, 
including 288 and 28 mutations annotated in 








No treatment recommendation 77 (15.2)
Conditional recommendation 14 (2.8)
Genetic counseling 4 (0.8)
Referral to organ board 1 (0.2)
Diagnostic recommendations, total No. (per-patient average) 305 (1.5)
Patients with diagnostic recommendations 172 (86.9)
Routine pathology 153 (89.0)
Extended genetic analysis* 69 (40.1)
Rebiopsy 15 (8.7)
Other 6 (3.5)
Diagnostic recommendations, not implemented 71 (23.3)
Patients with treatment recommendations 104 (52.5)
Implemented 33 (31.7)
Partial response 11 (33.3)
Stable disease 8 (24.2)
No. of treatment recommendations 104
Treatment recommendations, not implemented 71 (68.3)
NOTE: Data presented as No. (%) unless otherwise noted. See Figure 2 and Data Supplement for 
details of treatment recommendations and treatment recommendations not implemented.
*Whole-exome sequencing, RNA-seq.
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DGI and TARGET databases, respectively 
(Data Supplement). A total of 3,799 mutations 
were unknown to COSMIC (Data Supplement). 
The disease impact of non-hotspot mutations is 
more difficult to evaluate; however, it can lead to 
additional therapy-relevant insights. For exam-
ple, the ERBB2 S656F mutation might, accord-
ing to TARGET and DGI databases, constitute 
an activating mutation, therefore targetable by 
trastuzumab or lapatinib. The most frequently 
mutated genes were TP53 and BRAF (Fig 1C).
Overall, 71 of 305 diagnostic recommendations 
(23.3%) were not pursued. As shown in the 
Data Supplement, reasons for nonadherence 
included technical reasons (53.5%; mostly lack 
of sufficient tissue or DNA/RNA), patient death 
(12.7%), loss to follow-up (11.3%), medical rea-
sons (9.9%), or patient will (9.9%).
Treatment Recommendations
Specific treatment recommendations were given 
to 104 patients (Table 1; Fig 2) and mainly 
included off-label immune checkpoint inhibitor 
(CPI; n = 36; 34.6%), off-label targeted therapy 
(n = 19; 18.3%) with tyrosine kinase inhibitors, 
small molecules or antibodies that were not CPI 
(AB), trial inclusions (n = 13; 12.5%), and off- 
label combination treatments (n = 18; 17.3%; Data 
Supplement; Fig 2). Ninety of 104 treatment 
recommendations (86.5%) were either off-label 
therapies (n = 77) or trial inclusions (n = 13).
The implementation rate of treatment recom-
mendations was 31.7% (33 of 104). In-label 
recommendations were pursued in nine of 14 
cases (64.3%), whereas off-label recommenda-
tions and trial inclusions were implemented in 
only 28.6% (22 of 77) and 15.4% (two of 13) of 
the cases, respectively. Intended trial inclusion in 
11 patients failed because of poor performance 
status or patient death (n = 5), closed trial arm 
(n = 4), or patient will (n = 2). Main reasons for 
nonimplementation of treatment recommen-
dations included loss to follow-up (22.5%), 
recommendation in the future (19.7%), patient 
death (16.9%), patient will (14.1%), and medi-
cal reasons (14.1%; Data Supplement). Of note, 
evidence level of individual off-label recommen-
dations did not affect implementation rates (data 
not shown).
Clinical Outcome
In 33 patients with implemented treatment rec-
ommendations, partial remissions (PR) and sta-
ble diseases (SD) were seen in 11 (33.3%) and 
eight patients (24.2%; Table 1), respectively. 
After excluding in-label therapies, nine patients 
ascopubs.org/journal/po JCO™ Precision Oncology 5






Age, years, median (range) 58 (1-85)




Soft tissue 25 (12.6)
CNS 22 (11.1)












Head and neck 1 (0.5)
Others 13 (6.6)
Solid tumors (n = 189): stage at presentation
Complete remission 1 (0.5)
Localized disease 42 (22.2)
Metastatic disease 146 (77.3)
No. of previous lines of therapy, mean (range) 2.0 (0-11)
0 25 (12.6)
1 66 (33.3)
2 to 3 80 (40.4)
> 3 27 (13.6)
Reason for referral
Progressive disease after standard treatment 153 (77.3)
Rare tumor 33 (16.7)
Others 12 (6.1)
NOTE: Data presented as No. (%) unless otherwise noted.
Abbreviation: MTB, Molecular Tumor Board.
Downloaded from ascopubs.org by DFG Deutsche Forschungsgemeinschaft on September 19, 2021 from 137.250.100.044
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
achieved PR and five patients SD, resulting in 
an overall response rate of 4.6% (nine of 198 
patients) and a disease control rate (DCR) of 
7.1% (14 of 198 patients). Of note, all five 
patients experiencing SD experienced disease 
progression while receiving the previous treat-
ment. Of 14 responders receiving off-label ther-
apies, eight (57.1%) showed a progression-free 
survival (PFS) ratio (PFS2/PFS1; PFSr) > 1.3, 
supporting the impact of the recommended 
therapies.36 Three patients had a PFSr < 1.3 with 
ongoing responses, meaning that their PFSr is 
still increasing. Details about the outcome of 
responding patients are shown in Table 3. Two 
individual cases are shown in the Data Supple-
ment. Adherence to recommendations and out-
come according to type of treatment is shown 
in Fig 2. To assess whether implementation of 
treatment recommendations affected overall 
survival from first MTB discussion, we analyzed 
all patients with stage IV malignancies accord-
ing to three subgroups (n = 148; Fig 3). The 
median survival was not reached for patients 
with implemented treatment recommendations 
(n = 33 recommendations pursued; 95% CI, 9 
months to not reached), 8 months for patients 
for whom treatment recommendations were not 
implemented (n = 43 recommendations not pur-
sued; 95% CI, 3 to 10 months), and 10 months 
for patients who did not receive a treatment 
recommendation (n = 72 no recommendations; 
95% CI, 7 to 17 months). Patients who did not 
receive the recommended therapy because of 
death before treatment initiation (n = 12) were 
excluded from analysis.
DISCUSSION
In a cohort of 198 patients with mostly advanced 
malignancies beyond standard-of-care treatment, 
the Comprehensive Cancer Center Freiburg 
MTB identified actionable targets in 52.5% 
of the cases. Thirty-two percent received the 
recommended treatment. In 33 patients with 
implemented treatment recommendations the 
disease-control rate was 57.6%; it was 9.6% (19 
of 198 patients) for the entire cohort. Because 
the primary goal of an MTB is to give treatment 
recommendations beyond standard of care, we 
excluded five responders who received in-label 
6 ascopubs.org/journal/po JCO™ Precision Oncology
Patients discussed
(N = 198)





 Lost to FU















































































































 Lost to FU









 Lost to FU






Fig 2. Flow diagram of 
patients discussed at the 
Molecular Tumor Board. 
Responses were determined 
according to Response 
Evaluation Criteria in Solid 
Tumors (RECIST) version 
1.1. AB, antibody; Combi, 
combination; CPI, check-
point inhibitor; FU, fol-
low-up; NE, not evaluable; 
PD, progressive disease; PR, 
partial remission; SD, stable 
disease; SM, small molecule; 
TKI, tyrosine kinase inhibi-
tor; TT, targeted therapy.
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therapies resulting in a DCR of 7.1% (14 of 
198 patients). Other MTB case series reported 
DCRs in 3.2%, 7.8%, 9%, and 23.3% of the 
patients,38-41 suggesting that approximately 10% 
of patients might benefit from advanced person-
alized decision making.
Although molecular heterogeneity will limit the 
effect of therapeutic kinase inhibitors, higher 
nonsynonymous mutational burden can cre-
ate more neoantigens and therefore improve 
response rates to CPI.42,43 In our series, eight of 
11 patients (72.7%) showing PR received CPI, 
including seven off-label uses. Predictive bio-
markers for individualized immunotherapies are 
emerging and changing rapidly, with strong dif-
ferences between entities.44 Here, we used IHC 
for programmed cell death protein 1 (PD-1)/
PD-L1, tumor-infiltrating lymphocytes, micro-
satellite instability testing, and mutational bur-
den assessment as predictive biomarkers. In the 
near future, identifying individual cancer neoan-
tigens might allow a more precise prediction of 
responses to immunotherapies.45 This highlights 
the importance of an interdisciplinary MTB 
team that analyzes and interprets biomarkers to 
identify patients who might benefit from off- 
label immuno-oncology treatments.
In an MTB workflow, the portfolio of molecu-
lar diagnostic tests, as well as criteria to match 
and prioritize targeted therapies to molecular 
biomarkers, affects the probability to identify 
patients with actionable targets. Here, we used 
customized molecular diagnostics, including 
IHC/ISH and tNGS, in 153 out of 198 patients 
(77.3%) We implemented WES or RNA-
Seq analyses for patients with carcinomas of 
unknown primary and rare cancers and with 
diseases in which routine molecular diagnostics 
did not reveal any actionable target (18.2% of 
patients).
Multidimensional data have not been imple-
mented successfully to clinical routine, partly 
because of the complexity of developing and 
evaluating mathematical predictive models.46,47 
A recent analysis showed that an MTB workflow 
including WES/whole-genome sequencing, 
RNA-Seq, and data interpretation by a multi-
disciplinary board required a turnaround time 
of 6 weeks.48 Using high-dimensional molec-
ular data, the Molecular Screening for Cancer 
Treatment Optimization (MOSCATO-01) trial 
reported actionable mutations in less than half 
of the patients with advanced solid tumors,49 
and in the National Cancer Institute Molecular 
Analysis for Therapy Choice (NCI-MATCH) 
trial, only 9% of the patients could be assigned 
to one of the prespecified treatment arms.50 In 
contrast, our approach of customized molecular 
diagnostic testing with restricted use of extended 
genetic analyses (WES, RNA-Seq) allows a 
faster turnover with comparable rates of genet-
ically matched treatment recommendations. 
Therefore, average costs per case can be reduced 
at least by half when compared with perform-
ing extended molecular analysis for each patient. 
We identified actionable targets in 52.5% of 
cases and provided treatment recommendations 
with a median turnaround time of 28 days. To 
improve standardization and turnaround time, we 
recently implemented SOPs for diagnostic work- 
ups (Data Supplement). Our approach shares 
similarities with Memorial Sloan Kettering- 
Integrated Mutation Profiling of Actionable 
Cancer Targets (MSK-IMPACT), focusing on 
therapeutically targetable biomarkers for fast 
clinical decision making and referral of patients 
to available clinical trials.51
Targeted drug combinations might offer better 
DCR over single-agent therapies.52-55 In part, 
this is due to crosstalk between signaling path-
ways as well as spatial and temporal clonal het-
erogeneity, especially in patients with advanced 
cancer who failed standard-of-care treat-
ment.56,57 Most current programs for precision 
oncology use prespecified, genetically matched, 
single-agent treatments (NCI-MATCH, Clin-
icalTrials.gov identifier: NCT02465060; or 
Targeted Agent and Profiling Utilization Reg-
istry [TAPUR], ClinicalTrials.gov identi-
fier: NCT02693535). In our series, three of 19 





















Rec. pursued (n = 33); OS = not reached
Rec. not pursued (n = 43); OS = 8 months
No rec. (n = 72);  OS = 10 months
Fig 3. Survival analysis. 
The Kaplan-Meier curve 
shows the survival of the 
following three subgroups 
of patients with stage IV 
malignancies (n = 148): 
patients who implemented 
the treatment recommen-
dation (Rec. pursued,  
n = 33), patients who did not 
implement the treatment 
recommendation (Rec. 
not pursued, n = 43; of 
note: patients who did not 
receive the recommended 
therapy because of death 
before treatment initiation 
[n = 12] were excluded 
from analysis), and patients 
who did not receive a 
treatment recommendation 
(n = 72). The curve com-
parison with the log-rank 
(Mantel-Cox) test revealed 
statistical significant differ-
ences as shown on graph. 
OS, overall survival.  
(*) P < .01.
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treatments that successfully controlled disease 
(15.8%) included molecular combination treat-
ments (Fig 2). These patients did not suffer from 
grade 3 to 4 adverse effects, although treatment 
combinations may bear a higher risk of toxicity.58
Earlier referral to an MTB (eg, after failure of 
first-line treatment) might prevent the insti-
tution of ineffective treatments, improve the 
implementation rate, and increase the likelihood 
of success of molecular biomarker–matched 
treatments. In our series, patient death, patient 
preference, or medical reasons precluded imple-
mentation in 23.3% of diagnostic and 68.3% 
of treatment recommendations. The survival 
analysis revealed a significant overall survival 
advantage for patients with implemented MTB 
treatment recommendations (median overall 
survival not reached; 95% CI, 9 months to not 
reached) compared with patients where rec-
ommendations were not pursued (8 months; 
95% CI, 3 to 10 months; P = .002) as well as 
for patients without treatment recommendation 
(10 months; 95% CI, 7 to 17 months; P = .008). 
Because of the low sample size and the heteroge-
neous composition of patients in the cohorts, the 
validity of this survival analysis is limited.
Access to molecular biomarker–matched, off- 
label agents for cancer treatment is limited. In a 
recent single-center study, only 5% of molecular 
biomarker–matched treatment recommenda-
tions were implemented, mainly because of lim-
ited access to clinical trials or to restricted use 
of drugs outside their marketed label.59 Thus, it 
is crucial to build up platforms for patients and 
treating physicians to link individual molecular 
information of the tumor to appropriate nonap-
proved drugs and available clinical trials. To this 
end, MTB networks might implement SOPs 
for diagnostic work-ups and data interpreta-
tion and build alliances to governmental insti-
tutions and insurance companies to generate 
criteria for the financial coverage of molecular 
analyses and off-label treatments. Finally, an 
MTB is predestined to generate knowledge 
and evidence in oncology via single-person tri-
als instead of large, time- and cost-intensive 
clinical trials. In case of sequence variants with 
undetermined significance, precision oncology 
workflows should allow fast reverse translation 
of sequence variants into informative preclinical 
models. In a patient with melanoma, we identi-
fied a kinase-inactivating BRAF mutation (Data 
Supplement). In vitro characterization indicated 
antitumor activity of combined pan-RAF and 
mitogen-activated protein kinase kinase inhi-
bition and guided successful treatment with 
sorafenib and trametinib. In rare entities, and 
especially in the setting of treatment-refractory 
cancers, precision oncology networks should 
allow hypothesis-driven in vitro studies and val-
idation in small sets of individuals. Thus, within 
the concept of patient-centric, biomarker-driven 
trial designs,60 an MTB might constitute a criti-
cal tool to identify informative patients for clin-
ical trials of targeted therapies in rare molecular 
subgroups.
In summary, this MTB experience illustrates 
that patient management, on the basis of indi-
vidual molecular biomarker profiling and analysis, 
is feasible in patients beyond standard-of-care 
treatment. We show a high proportion of trial- 
and off-label treatment recommendations (86.5%) 
and a DCR for off-label treatments of 7.1%. In 
cases where no approved treatment is available, 
an MTB might allow molecular biomarker–
matched off-label use of approved drugs across 
entity barriers or alternatively facilitate the 
access to therapeutic basket trials.
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Fig A1. Molecular 
Tumor Board (MTB) work-
flow. TOS, Tumorboard 
Online System.
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